BIOMAT Database Logo BIOMAT Database Logo

[Decreasing effect of DL-alpha-methylthyroxine-ethylester, D-thyroxine (DT4), D-triiodothyronine (DT3) and a combination of DT4 + DT3 on serum lipids in primary hyperlipoproteinemia Type IIa and b]. 1974

T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper

UI MeSH Term Description Entries
D008053 Lipid Mobilization LIPOLYSIS of stored LIPIDS in the ADIPOSE TISSUE to release FREE FATTY ACIDS. Mobilization of stored lipids is under the regulation of lipolytic signals (CATECHOLAMINES) or anti-lipolytic signals (INSULIN) via their actions on the hormone-sensitive LIPASE. This concept does not include lipid transport. Lipid Mobilizations,Mobilization, Lipid,Mobilizations, Lipid
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D013974 Thyroxine The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D014284 Triiodothyronine A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. Liothyronine,T3 Thyroid Hormone,3,3',5-Triiodothyronine,Cytomel,Liothyronine Sodium,Thyroid Hormone, T3

Related Publications

T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia.
March 1980, Atherosclerosis,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
January 1983, Arzneimittel-Forschung,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
The effect of beta-pyridylcarbinol on lipoprotein lipids in primary type IIa hyperlipoproteinemia.
September 1979, Atherosclerosis,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
The effect of cholestyramine on lipoprotein lipids in patients with primary type IIA hyperlipoproteinemia.
July 1979, Atherosclerosis,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Therapy of hyperlipoproteinemias type II a and II b using dextro-thyroxine or D,L-alpha-methyl-thyroxine-ethylester].
January 1972, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
January 1983, Arzneimittel-Forschung,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.
September 1987, Arzneimittel-Forschung,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Serum levels of thyrotropin triiodothyronine, thyroxine and thyroxine-binding proteins in patients with coronary disease and hyperlipoproteinemia of the IIA and IIB types].
May 1979, Wiadomosci lekarskie (Warsaw, Poland : 1960),
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Type II primary hyperlipoproteinemia: effect of dietary treatment and cholestyramine on serum lipids and lipoproteins].
January 1976, Vnitrni lekarstvi,
T Koschinsky, and F A Gries, and K H Vogelberg, and H Miss, and K Jahnke, and H Canzler, and F A Horster, and J Herrmann, and W Wildmeister, and H L Krüskemper
[Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
January 1977, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
Copied contents to your clipboard!